Eisai Co., Ltd. (ESAIY) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Mit einem Kurs von $ ist Eisai Co., Ltd. (ESAIY) ein Healthcare-Unternehmen mit einer Bewertung von 0. Die Aktie erzielt 55/100, eine moderate Bewertung basierend auf 9 quantitativen KPIs.
Zuletzt analysiert: 17. März 2026Eisai Co., Ltd. (ESAIY) Gesundheitswesen & Pipeline-Uebersicht
Eisai Co., Ltd., a Japanese pharmaceutical company, specializes in oncology and neurology drugs, holding a significant position in Alzheimer's disease treatment with Aricept and expanding its oncology portfolio with Lenvima, while navigating a competitive landscape and strategic collaborations.
Investmentthese
Eisai Co., Ltd. presents a mixed investment thesis. The company's established presence in the Alzheimer's disease market with Aricept and its growing oncology portfolio with Lenvima provide a stable revenue base. The company's profit margin stands at 5.3% with a gross margin of 77.8%. Upcoming data from its collaboration with Bristol Myers Squibb on farletuzumab ecteribulin antibody drug conjugate could serve as a catalyst. However, the company faces competition from generic drug manufacturers and potential regulatory challenges. The stock's beta of -0.19 suggests low volatility relative to the market. Investors should monitor the success of its pipeline products and the impact of generic competition on Aricept sales.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Eisai Co., Ltd. has a market capitalization of $8.54 billion, reflecting its substantial presence in the pharmaceutical industry.
- The company's P/E ratio is 32.08, indicating the price investors are willing to pay for each dollar of earnings.
- Eisai's gross margin of 77.8% demonstrates efficient cost management in its manufacturing and sales processes.
- The company offers a dividend yield of 3.29%, providing a steady income stream for investors.
- Eisai's strategic collaboration with Bristol Myers Squibb enhances its oncology pipeline and potential for future growth.
Wettbewerber & Vergleichsunternehmen
Staerken
- Strong presence in Alzheimer's disease treatment with Aricept.
- Growing oncology portfolio with Lenvima.
- Strategic collaboration with Bristol Myers Squibb.
- Established global presence and distribution network.
Schwaechen
- Reliance on a few key products for revenue.
- Exposure to generic competition.
- High R&D costs.
- Dependence on regulatory approvals.
Katalysatoren
- Ongoing: Continued clinical trial progress for Lenvima in new cancer indications.
- Upcoming: Data releases from the collaboration with Bristol Myers Squibb on farletuzumab ecteribulin antibody drug conjugate.
- Ongoing: Expansion of Eisai's presence in emerging markets, such as China and India.
Risiken
- Ongoing: Generic erosion of Aricept sales due to patent expiration.
- Potential: Regulatory challenges and delays in drug approvals.
- Potential: Increased competition from other pharmaceutical companies.
- Potential: Economic downturns affecting healthcare spending.
- Ongoing: Currency fluctuations impacting the value of ADRs.
Wachstumschancen
- Expansion of Oncology Portfolio: Eisai's collaboration with Bristol Myers Squibb on farletuzumab ecteribulin antibody drug conjugate represents a significant growth opportunity in the oncology market. The global oncology market is projected to reach $286.6 billion by 2030. Successful development and commercialization of this drug could significantly boost Eisai's revenue and market share. The ongoing clinical trials and regulatory approvals will determine the timeline for this growth driver.
- Alzheimer's Disease Treatment Advancements: Eisai's continued research and development in Alzheimer's disease treatments offer substantial growth potential. The aging global population is driving increased demand for effective Alzheimer's therapies. Eisai's Aricept has been a cornerstone in this area, and new advancements could solidify its leadership. The timeline depends on clinical trial outcomes and regulatory approvals, with potential for significant impact within the next 3-5 years.
- Geographic Expansion into Emerging Markets: Eisai has the opportunity to expand its presence in emerging markets, such as China and India, where healthcare spending is rapidly increasing. These markets offer significant growth potential for Eisai's existing product portfolio and pipeline drugs. The timeline for this expansion depends on regulatory approvals and market entry strategies, with potential for steady growth over the next 5-10 years.
- Strategic Acquisitions and Partnerships: Eisai can pursue strategic acquisitions and partnerships to expand its product portfolio and access new technologies. This approach can accelerate growth and diversify the company's revenue streams. The timing and impact of these opportunities are dependent on market conditions and available targets, with potential for transformative deals in the coming years.
- Development of Novel Therapies for Neurological Disorders: Eisai's focus on neurology provides a platform for developing novel therapies for other neurological disorders beyond Alzheimer's disease. The market for neurological disorder treatments is growing, driven by increasing prevalence and unmet medical needs. Successful development and commercialization of new therapies could significantly contribute to Eisai's long-term growth. The timeline depends on research and development progress and regulatory approvals.
Chancen
- Expansion into emerging markets.
- Development of novel therapies for neurological disorders.
- Strategic acquisitions and partnerships.
- Advancements in Alzheimer's disease treatment.
Risiken
- Generic erosion of key products.
- Increased competition from other pharmaceutical companies.
- Stringent regulatory requirements.
- Economic downturns affecting healthcare spending.
Wettbewerbsvorteile
- Patented pharmaceutical products provide market exclusivity.
- Strong brand recognition in specific therapeutic areas.
- Established distribution network and sales force.
- Strategic collaborations with other pharmaceutical companies.
Ueber ESAIY
Eisai Co., Ltd., established in 1941 and headquartered in Tokyo, Japan, is a global pharmaceutical company committed to innovative solutions for health and well-being. Originally named Nihon Eisai Co., Ltd., the company adopted its current name in 1955. Eisai focuses on research and development, manufacturing, sales, and import/export of pharmaceutical products. The company's diverse portfolio includes treatments for various therapeutic areas, including oncology, neurology, and gastrointestinal disorders. Key products include Aricept, a leading treatment for Alzheimer's disease, and Lenvima, an anticancer agent used in the treatment of thyroid cancer and hepatocellular carcinoma. Eisai also offers Dayvigo for insomnia, Halaven for breast cancer, and Fycompa for epilepsy. The company has a strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin antibody drug conjugate, enhancing its oncology pipeline. Eisai's commitment to addressing unmet medical needs and improving patient outcomes has solidified its position as a key player in the global pharmaceutical industry.
Was das Unternehmen tut
- Researches and develops pharmaceutical products.
- Manufactures pharmaceutical drugs.
- Sells and markets pharmaceutical products globally.
- Imports and exports pharmaceutical products.
- Focuses on treatments for oncology, neurology, and gastrointestinal disorders.
- Collaborates with other pharmaceutical companies for drug development and commercialization.
Geschaeftsmodell
- Develops and patents innovative pharmaceutical products.
- Generates revenue through the sale of prescription drugs.
- Partners with other companies for co-development and commercialization.
- Invests in research and development to create new therapies.
Branchenkontext
Eisai Co., Ltd. operates within the competitive pharmaceutical industry, facing challenges from both established players and generic drug manufacturers. The industry is characterized by high R&D costs, stringent regulatory requirements, and patent expirations. Eisai's focus on specialty drugs, particularly in oncology and neurology, positions it in high-growth areas. The global pharmaceutical market is expected to continue expanding, driven by an aging population and increasing demand for innovative treatments. Eisai's strategic collaborations and pipeline development are crucial for maintaining its competitive edge in this dynamic landscape.
Wichtige Kunden
- Patients requiring treatments for various diseases.
- Hospitals and clinics.
- Pharmacies and drug distributors.
- Healthcare providers.
Finanzdaten
Chart & Info
Eisai Co., Ltd. (ESAIY) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer ESAIY.
Kursziele
Wall-Street-Kurszielanalyse fuer ESAIY.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von ESAIY auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Haruo Naito
CEO
Haruo Naito has served as the CEO of Eisai Co., Ltd. He has been with Eisai for many years, holding various leadership positions within the company. His career has been dedicated to the pharmaceutical industry, with a focus on research and development, strategic planning, and global market expansion. He is responsible for managing 11067 employees. Naito's leadership is focused on innovation and addressing unmet medical needs.
Erfolgsbilanz: Under Haruo Naito's leadership, Eisai has focused on expanding its oncology portfolio and strengthening its position in the Alzheimer's disease market. Key milestones include the strategic collaboration with Bristol Myers Squibb and the continued development of innovative therapies. He has overseen the growth of Lenvima and the continued success of Aricept. Naito has emphasized a patient-centric approach and a commitment to addressing global health challenges.
Eisai Co., Ltd. ADR-Informationen Nicht gesponsert
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. ESAIY is an ADR that allows U.S. investors to invest in Eisai Co., Ltd. without directly purchasing shares on the Tokyo Stock Exchange. It simplifies trading and reduces complexities associated with international investing.
- Heimatmarkt-Ticker: Tokyo Stock Exchange, Japan
- ADR-Stufe: 1
- ADR-Verhaeltnis: 1:1
- Heimatmarkt-Ticker: ESAI
ESAIY OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies in this tier often have limited or no financial disclosure requirements, and they may not meet the minimum listing standards of major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the lack of transparency and regulatory oversight.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure increases the risk of investing in ESAIY on the OTC market.
- Low trading volume and wide bid-ask spreads can lead to price volatility and difficulty in executing trades.
- Lack of regulatory oversight increases the potential for fraud or mismanagement.
- The company may not meet the listing standards of major exchanges, indicating potential financial or operational challenges.
- The OTC Other tier carries a higher risk of delisting or trading suspension.
- Verify the company's registration and legal status.
- Obtain and review any available financial reports or disclosures.
- Assess the company's management team and their track record.
- Research the company's products, services, and market position.
- Evaluate the company's competitive landscape and potential risks.
- Consult with a financial advisor or legal professional.
- Understand the risks associated with investing in OTC securities.
- Eisai Co., Ltd. is a well-established pharmaceutical company with a global presence.
- The company has a diverse portfolio of pharmaceutical products and a history of innovation.
- Eisai has strategic collaborations with other reputable pharmaceutical companies.
- The company is listed on the Tokyo Stock Exchange (ESAI), providing some level of regulatory oversight.
- Eisai has a dedicated investor relations team and provides some information to investors.
Was Anleger ueber Eisai Co., Ltd. (ESAIY) wissen wollen
What are the key factors to evaluate for ESAIY?
Eisai Co., Ltd. (ESAIY) currently holds an AI score of 55/100, indicating moderate score. Key strength: Strong presence in Alzheimer's disease treatment with Aricept.. Primary risk to monitor: Ongoing: Generic erosion of Aricept sales due to patent expiration.. This is not financial advice.
How frequently does ESAIY data refresh on this page?
ESAIY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ESAIY's recent stock price performance?
Recent price movement in Eisai Co., Ltd. (ESAIY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Strong presence in Alzheimer's disease treatment with Aricept.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ESAIY overvalued or undervalued right now?
Determining whether Eisai Co., Ltd. (ESAIY) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ESAIY?
Before investing in Eisai Co., Ltd. (ESAIY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding ESAIY to a portfolio?
Potential reasons to consider Eisai Co., Ltd. (ESAIY) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Strong presence in Alzheimer's disease treatment with Aricept.. Additionally: Growing oncology portfolio with Lenvima.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of ESAIY?
Yes, most major brokerages offer fractional shares of Eisai Co., Ltd. (ESAIY) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track ESAIY's earnings and financial reports?
Eisai Co., Ltd. (ESAIY) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for ESAIY earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Information is based on available data and may be subject to change.
- Investment decisions should be based on individual research and risk assessment.